Karyopharm Therapeutics (NASDAQ:KPTI) Buy Rating Maintained Today By H.C. Wainwright; The Target Price is Set to $29

Investors sentiment increased to 1.31 in Q4 2018. Its up 0.29, from 1.02 in 2018Q3. It improved, as 11 investors sold Karyopharm Therapeutics Inc. shares while 31 reduced holdings. 20 funds opened positions while 35 raised stakes. 48.23 million shares or 17.97% more from 40.88 million shares in 2018Q3 were reported.

Franklin Resources reported 1.80 million shares. Voya Investment Mgmt Limited Liability Co has invested 0% in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). 31,916 are owned by American Grp. California State Teachers Retirement reported 75,930 shares. Strs Ohio holds 0% or 24,200 shares. Emerald Mutual Fund Advisers holds 0.37% or 647,307 shares in its portfolio. 85,150 were reported by Swiss Natl Bank. Prelude Capital Management Ltd Limited Liability Company holds 357 shares. Dimensional Fund L P invested in 0% or 673,774 shares. Vanguard Gru holds 0% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) for 1.73 million shares. Wellington Limited Liability Partnership invested in 0.02% or 8.22 million shares. Weiss Multi has invested 0.01% of its portfolio in Karyopharm Therapeutics Inc. (NASDAQ:KPTI). Teachers Retirement Sys Of The State Of Kentucky invested in 0% or 18,700 shares. Blackrock Incorporated reported 4.26 million shares. Fmr Llc owns 1.88 million shares for 0% of their portfolio.

Since September 18, 2018, it had 0 insider buys, and 18 sales for $9.78 million activity. On Tuesday, September 18 Kauffman Michael sold $182,615 worth of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) or 10,000 shares. Chione Ltd sold $619,114 worth of stock or 149,624 shares.

Karyopharm Therapeutics (NASDAQ:KPTI) Rating Reaffirmed

Stock analysts at H.C. Wainwright now has a $29 PT on Karyopharm Therapeutics (NASDAQ:KPTI). H.C. Wainwright and their recent PT would suggest a potential upside of 515.71 % from the company’s close price. The rating has been revealed to investors in a research report on Friday morning.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Ratings Coverage

Among 6 analysts covering Karyopharm Therapeutics (NASDAQ:KPTI), 4 have Buy rating, 0 Sell and 2 Hold. Therefore 67% are positive. Karyopharm Therapeutics has $30 highest and $6 lowest target. $13.67’s average target is 190.23% above currents $4.71 stock price. Karyopharm Therapeutics had 10 analyst reports since November 9, 2018 according to SRatingsIntel. The rating was upgraded by Wedbush on Friday, November 9 to “Outperform”. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Hold” rating by J.P. Morgan on Friday, March 1. RBC Capital Markets maintained the stock with “Buy” rating in Wednesday, February 27 report. H.C. Wainwright maintained the shares of KPTI in report on Friday, February 22 with “Buy” rating. Bank of America upgraded the stock to “Neutral” rating in Thursday, January 3 report. The firm earned “Buy” rating on Wednesday, February 27 by Wedbush. The stock of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) earned “Neutral” rating by JP Morgan on Friday, March 1. The firm earned “Buy” rating on Wednesday, February 27 by Robert W. Baird.

The stock increased 7.05% or $0.31 during the last trading session, reaching $4.71. About 9.52 million shares traded or 541.22% up from the average. Karyopharm Therapeutics Inc. (NASDAQ:KPTI) has declined 70.94% since March 16, 2018 and is downtrending. It has underperformed by 75.31% the S&P500.

Analysts await Karyopharm Therapeutics Inc. (NASDAQ:KPTI) to report earnings on May, 9. They expect $-0.86 earnings per share, down 10.26 % or $0.08 from last year’s $-0.78 per share. After $-0.96 actual earnings per share reported by Karyopharm Therapeutics Inc. for the previous quarter, Wall Street now forecasts -10.42 % EPS growth.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. The company has market cap of $286.65 million. The Company’s lead drug candidate is Selinexor, which is in Phase IIb clinical trial for patients with heavily pretreated multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for relapsed/refractory multiple myeloma; Phase II/III clinical trial for patients with relapsed and/or refractory multiple myeloma; Phase II clinical study to treat acute myeloid leukemia; Phase IIb clinical trial for patients with diffuse large B-cell lymphoma; and Phase II/III clinical trial to treat liposarcoma. It currently has negative earnings. The firm is also developing KPT-8602 that is in Phase I/II study for patients with relapsed/refractory multiple myeloma; KPT-9274, which is in Phase I clinical trial for patients with advanced solid malignancies or non-HodgkinÂ’s lymphoma; KPT-335, which is in Phase I clinical trial for the treatment of viral indications; and KPT-350 that is in preclinical stage to treat neurological disorders, and inflammatory and autoimmune diseases.

More notable recent Karyopharm Therapeutics Inc. (NASDAQ:KPTI) news were published by: Seekingalpha.com which released: “Achieve Life Sciences and Karyopharm Therapeutics among healthcare gainers; Biocept and BioScrip among losers – Seeking Alpha” on March 15, 2019, also Streetinsider.com with their article: “Karyopharm Therapeutics (KPTI) Confirms Trading Halted Ahead of FDA Advisory Committee Meeting to Discuss Selinexor – StreetInsider.com” published on February 26, 2019, Seekingalpha.com published: “Karyopharm socked by FDA briefing docs – Seeking Alpha” on February 22, 2019. More interesting news about Karyopharm Therapeutics Inc. (NASDAQ:KPTI) were released by: Seekingalpha.com and their article: “New CFO at Karyopharm Therapeutics – Seeking Alpha” published on February 25, 2019 as well as Schaeffersresearch.com‘s news article titled: “Dow Futures Lower Amid US-North Korea Arms Meeting – Schaeffers Research” with publication date: February 27, 2019.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.